Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Choosing the right investment app can be daunting for beginners. We break down the best options to help you start investing confidently.
24,582 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
As markets stay choppy in early 2026, retirees turn to monthly dividend stocks for predictable income and capital pre...
NEAR token surged recently, signaling renewed market interest. This guide unpacks the drivers behind the near protoco...
A viral tale about AI and a dog's cancer sparked a wave of hype. This article unpacks what actually happened, what sc...
Alphabet’s Q1 2026 results show a rapid profit pace that dwarfs Meta’s earnings, underscoring a widening gap in AI-dr...
Today’s market moved in Ford’s favor as analysts primed optimism around Ford’s energy initiatives alongside its tradi...
A mid-sized fund wrapped up a $9 million exit from a major pawn shop operator after a rally of about 150% over the ye...
As rates stay elevated and market conditions shift, a retiree with $150,000 mortgage faces a classic question: should...
As SpaceX opens trading, savvy investors wonder how much upside the IPO price may still hold. This deep-dive walks th...
A surprising shift in mega-cap leadership had investors buzzing: SpaceX briefly topped Amazon in market value. This p...
When CODA reports its Q2 2026 results, the focus shifts from headlines to signals—backlog, margins, and customer wins...
Investing in tomorrow’s energy tech can feel risky. This article outlines how a compact, early-stage stock could grow...